Levofloxacin Hemihydrate-Adorned Floating Drug Delivery System to Ameliorate H. Pylori Infection: Formulation Development, Optimization, and Characterization.

Authors

Sheikh Muhammad Mishkat Ullah, Sheikh Abdur Rashid, Nauman Rahim Khan, Kashif Maqbool Khan, Muhammad Khurshid Alam Shah, Faiza Naseem, Amina Riaz, Pervaiz Akhtar Shah, Farooq Bashir Butt, Mobina Manzoor, Syed Zia Husnain, Nisar Ahmed Shahwani

Published in

Drug development and industrial pharmacy. Pages 1-17. Sep 04, 2026. Epub Sep 04, 2026.

Abstract

This study focused on developing and characterizing Levofloxacin hemihydrate floating bioadhesive tablets for the treatment of Helicobacter pylori (H. pylori) infection.
This study demonstrates a promising gastroretentive and bioadhesive drug delivery system that enhances the effectiveness of levofloxacin in the stomach for targeted H. pylori infection treatment.
Floating bio-adhesive tablets were prepared by direct compression using sodium bicarbonate (NaHCO3) as a gas-generating agent and HPMC K4M/chitosan and carbopol 940P/sodium alginate as release retardants and bio-adhesives. Pre-formulation flow properties were evaluated. Tablets were characterized by physicochemical parameters, bioadhesion on goat stomach mucosa, and FTIR, which confirmed drug-excipient compatibility.
The optimized formulation (FT7) showed a buoyancy lag time of 62.59 ± 6.83 second, a total floating time of more than 12h, a swelling index of 81.89%, and a bioadhesion strength of 28.19 ± 5.12g. The formulation remained physically stable after three months of storage at 40 °C and 75% RH. Drug release followed a non-Fickian diffusion mechanism (n = 0.514) and best fit the Korsmeyer-Peppas model (R2 = 0.989). In vitro and in vivo mucoadhesion studies demonstrated good retention of the tablet in the rabbit stomach for over 12 h. In-vivo barium sulfate X-ray imaging further confirmed that the tablet remained floating in the stomach 12 hours after oral administration.
A matrix-floating bio-adhesive tablet containing levofloxacin hemihydrate was successfully developed to effectively eliminate H. pylori infection.

PMID:
42698273
Bibliographic data and abstract were imported from PubMed on 05 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.